Three insights:
1. Tactoset is intended for the treatment of bone voids and other bone defects caused by trauma or age-related degeneration.
2. The therapy fuses calcium phosphate with Anika’s hyaluronic acid to enhance procedural efficiency and ease of use.
3. Tactoset is provided in a kit with an aqueous solution in a pre-loaded syringe and a dry powder that must be mixed intraoperatively to form a cohesive paste prior to administration.
More articles on devices:
6 hospitals adding robotic systems for spine, orthopedics
Royal Biologics launches allograft for spine, neurosurgery
17 patients sue Mizzou BioJoint Center over knee replacement failures
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.